Found: 41
Select item for more details and to access through your institution.
Clinical pharmacokinetics and pharmacodynamics of venetoclax, a selective B‐cell lymphoma‐2 inhibitor.
- Published in:
- CTS: Clinical & Translational Science, 2024, v. 17, n. 5, p. 1, doi. 10.1111/cts.13807
- By:
- Publication type:
- Article
Venetoclax pharmacokinetics in participants with end‐stage renal disease undergoing haemodialysis.
- Published in:
- British Journal of Clinical Pharmacology, 2024, v. 90, n. 3, p. 748, doi. 10.1111/bcp.15935
- By:
- Publication type:
- Article
Venetoclax in biomarker‐selected multiple myeloma patients: Impact of exposure on clinical efficacy and safety.
- Published in:
- Hematological Oncology, 2024, v. 42, n. 1, p. 1, doi. 10.1002/hon.3222
- By:
- Publication type:
- Article
Pooled Population Pharmacokinetic Analyses of Venetoclax in Patients Across Indications and Healthy Subjects from Phase 1, 2, and 3 Clinical Trials.
- Published in:
- Journal of Clinical Pharmacology, 2023, v. 63, n. 8, p. 950, doi. 10.1002/jcph.2248
- By:
- Publication type:
- Article
Venetoclax Penetrates the Blood Brain Barrier: A Pharmacokinetic Analysis in Pediatric Leukemia Patients.
- Published in:
- Journal of Cancer, 2023, v. 14, n. 7, p. 1151, doi. 10.7150/jca.81795
- By:
- Publication type:
- Article
Impact of Multiple Concomitant CYP3A Inhibitors on Venetoclax Pharmacokinetics: A PBPK and Population PK‐Informed Analysis.
- Published in:
- Journal of Clinical Pharmacology, 2023, v. 63, n. 1, p. 119, doi. 10.1002/jcph.2140
- By:
- Publication type:
- Article
A Critical Review of Chloroquine and Hydroxychloroquine as Potential Adjuvant Agents for Treating People with Cancer.
- Published in:
- Future Pharmacology, 2022, v. 2, n. 4, p. 431, doi. 10.3390/futurepharmacol2040028
- By:
- Publication type:
- Article
Pharmacokinetics and Exposure-Response Analysis of Venetoclax + Obinutuzumab in Chronic Lymphocytic Leukemia: Phase 1b Study and Phase 3 CLL14 Trial.
- Published in:
- Advances in Therapy, 2022, v. 39, n. 8, p. 3635, doi. 10.1007/s12325-022-02170-w
- By:
- Publication type:
- Article
Bioavailability Evaluation of Venetoclax Lower-Strength Tablets and Oral Powder Formulations to Establish Interchangeability with the 100 mg Tablet.
- Published in:
- Clinical Drug Investigation, 2022, v. 42, n. 8, p. 657, doi. 10.1007/s40261-022-01172-4
- By:
- Publication type:
- Article
Venetoclax exposure‐efficacy and exposure‐safety relationships in patients with treatment‐naïve acute myeloid leukemia who are ineligible for intensive chemotherapy.
- Published in:
- Hematological Oncology, 2022, v. 40, n. 2, p. 269, doi. 10.1002/hon.2964
- By:
- Publication type:
- Article
Population Pharmacokinetics and Exposure–Response Analyses for Venetoclax in Combination with R-CHOP in Relapsed/Refractory and Previously Untreated Patients with Diffuse Large B Cell Lymphoma.
- Published in:
- Advances in Therapy, 2022, v. 39, n. 1, p. 598, doi. 10.1007/s12325-021-01919-z
- By:
- Publication type:
- Article
A microdosing framework for absolute bioavailability assessment of poorly soluble drugs: A case study on cold‐labeled venetoclax, from chemistry to the clinic.
- Published in:
- CTS: Clinical & Translational Science, 2022, v. 15, n. 1, p. 244, doi. 10.1111/cts.13144
- By:
- Publication type:
- Article
Industrial Perspective on the Benefits Realized From the FDA's Model‐Informed Drug Development Paired Meeting Pilot Program.
- Published in:
- Clinical Pharmacology & Therapeutics, 2021, v. 110, n. 5, p. 1172, doi. 10.1002/cpt.2265
- By:
- Publication type:
- Article
Venetoclax in combination with azacitidine in Japanese patients with acute myeloid leukaemia: phase 1 trial findings.
- Published in:
- Japanese Journal of Clinical Oncology, 2021, v. 51, n. 6, p. 857, doi. 10.1093/jjco/hyab018
- By:
- Publication type:
- Article
Targeting BCL‐2 with venetoclax and dexamethasone in patients with relapsed/refractory t(11;14) multiple myeloma.
- Published in:
- American Journal of Hematology, 2021, v. 96, n. 4, p. 418, doi. 10.1002/ajh.26083
- By:
- Publication type:
- Article
Dose adjustment of venetoclax when co-administered with posaconazole: clinical drug–drug interaction predictions using a PBPK approach.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2021, v. 87, n. 4, p. 465, doi. 10.1007/s00280-020-04179-w
- By:
- Publication type:
- Article
Phase 1/2 study of venetoclax, a BCL-2 inhibitor, in Japanese patients with relapsed or refractory chronic lymphocytic leukemia and small lymphocytic lymphoma.
- Published in:
- International Journal of Hematology, 2021, v. 113, n. 3, p. 370, doi. 10.1007/s12185-020-03024-3
- By:
- Publication type:
- Article
Science and Evidence‐Based Review and Approval of COVID‐19 Vaccines: A Statement of Support for the US FDA.
- Published in:
- Journal of Clinical Pharmacology, 2021, v. 61, n. 3, p. 277, doi. 10.1002/jcph.1794
- By:
- Publication type:
- Article
Integrated Mechanistic Model of Minimal Residual Disease Kinetics With Venetoclax Therapy in Chronic Lymphocytic Leukemia.
- Published in:
- Clinical Pharmacology & Therapeutics, 2021, v. 109, n. 2, p. 424, doi. 10.1002/cpt.2005
- By:
- Publication type:
- Article
Assessment of Clinical Drug‐Drug Interactions of Elagolix, a Gonadotropin‐Releasing Hormone Receptor Antagonist.
- Published in:
- Journal of Clinical Pharmacology, 2020, v. 60, n. 12, p. 1606, doi. 10.1002/jcph.1689
- By:
- Publication type:
- Article
Semimechanistic Modeling to Guide Venetoclax Coadministration with Ritonavir and Digoxin.
- Published in:
- CTS: Clinical & Translational Science, 2020, v. 13, n. 3, p. 555, doi. 10.1111/cts.12739
- By:
- Publication type:
- Article
Bayesian Population Model of the Pharmacokinetics of Venetoclax in Combination with Rituximab in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia: Results from the Phase III MURANO Study.
- Published in:
- 2019
- By:
- Publication type:
- journal article
Model‐Informed Dosing of Venetoclax in Healthy Subjects: An Exposure−Response Analysis.
- Published in:
- CTS: Clinical & Translational Science, 2019, v. 12, n. 6, p. 625, doi. 10.1111/cts.12665
- By:
- Publication type:
- Article
Optimizing venetoclax dose in combination with low intensive therapies in elderly patients with newly diagnosed acute myeloid leukemia: An exposure-response analysis.
- Published in:
- 2019
- By:
- Publication type:
- journal article
Pharmacokinetics of the BCL-2 Inhibitor Venetoclax in Subjects with Hepatic Impairment.
- Published in:
- 2019
- By:
- Publication type:
- journal article
Power Determination During Drug Development: Is Optimizing the Sample Size Based on Exposure‐Response Analyses Underutilized?
- Published in:
- CPT: Pharmacometrics & Systems Pharmacology, 2019, v. 8, n. 3, p. 138, doi. 10.1002/psp4.12380
- By:
- Publication type:
- Article
Effect of Azithromycin on Venetoclax Pharmacokinetics in Healthy Volunteers: Implications for Dosing Venetoclax with P-gp Inhibitors.
- Published in:
- 2018
- By:
- Publication type:
- journal article
Use of depth of response to predict progression-free survival in relapsed or refractory multiple myeloma: Evaluation of results from 102 clinical trials.
- Published in:
- 2018
- By:
- Publication type:
- journal article
Statins enhance efficacy of venetoclax in blood cancers.
- Published in:
- Science Translational Medicine, 2018, v. 10, n. 445, p. 1, doi. 10.1126/scitranslmed.aaq1240
- By:
- Publication type:
- Article
Pharmacokinetics of the BCL‐2 Inhibitor Venetoclax in Healthy Chinese Subjects.
- Published in:
- Clinical Pharmacology in Drug Development, 2018, v. 7, n. 4, p. 435, doi. 10.1002/cpdd.395
- By:
- Publication type:
- Article
Relationship between response rates and median progression-free survival in non-Hodgkin's lymphoma: A meta-analysis of published clinical trials.
- Published in:
- 2018
- By:
- Publication type:
- journal article
Relationship between venetoclax exposure, rituximab coadministration, and progression-free survival in patients with relapsed or refractory chronic lymphocytic leukemia: demonstration of synergy.
- Published in:
- 2017
- By:
- Publication type:
- journal article
Quantitative Prediction of the Effect of CYP3A Inhibitors and Inducers on Venetoclax Pharmacokinetics Using a Physiologically Based Pharmacokinetic Model.
- Published in:
- Journal of Clinical Pharmacology, 2017, v. 57, n. 6, p. 796, doi. 10.1002/jcph.858
- By:
- Publication type:
- Article
Impact of Venetoclax Exposure on Clinical Efficacy and Safety in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia.
- Published in:
- 2017
- By:
- Publication type:
- journal article
Effect of ketoconazole, a strong CYP3A inhibitor, on the pharmacokinetics of venetoclax, a BCL-2 inhibitor, in patients with non-Hodgkin lymphoma.
- Published in:
- British Journal of Clinical Pharmacology, 2017, v. 83, n. 4, p. 846, doi. 10.1111/bcp.13175
- By:
- Publication type:
- Article
Pharmacokinetics of Venetoclax, a Novel BCL-2 Inhibitor, in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Non-Hodgkin Lymphoma.
- Published in:
- Journal of Clinical Pharmacology, 2017, v. 57, n. 4, p. 484, doi. 10.1002/jcph.821
- By:
- Publication type:
- Article
Evaluation of Rifampin's Transporter Inhibitory and CYP3A Inductive Effects on the Pharmacokinetics of Venetoclax, a BCL-2 Inhibitor: Results of a Single- and Multiple-Dose Study.
- Published in:
- Journal of Clinical Pharmacology, 2016, v. 56, n. 11, p. 1335, doi. 10.1002/jcph.730
- By:
- Publication type:
- Article
Effect of Low- and High-Fat Meals on the Pharmacokinetics of Venetoclax, a Selective First-in-Class BCL-2 Inhibitor.
- Published in:
- Journal of Clinical Pharmacology, 2016, v. 56, n. 11, p. 1355, doi. 10.1002/jcph.741
- By:
- Publication type:
- Article
Venetoclax does not prolong the QT interval in patients with hematological malignancies: an exposure-response analysis.
- Published in:
- 2016
- By:
- Publication type:
- journal article
Pharmacokinetic Enhancement in HIV Antiretroviral Therapy: A Comparison of Ritonavir and Cobicistat.
- Published in:
- AIDS Reviews, 2015, v. 17, n. 1, p. 37
- By:
- Publication type:
- Article
Monte Carlo simulation analysis of ceftobiprole, dalbavancin, daptomycin, tigecycline, linezolid and vancomycin pharmacodynamics against intensive care unit-isolated methicillin-resistant Staphylococcus aureus.
- Published in:
- Clinical & Experimental Pharmacology & Physiology, 2014, v. 41, n. 6, p. 437, doi. 10.1111/1440-1681.12195
- By:
- Publication type:
- Article